Molecular targeting of BCl-2 in oral cancer cells by nordentatin: An in silico docking and molecular dynamics study
Main Article Content
Abstract
Background: Oral cancer is a major problem in dentistry and remains a major global health issue. In oral cancer, BCL-2, which plays a role in regulating cell death, is overexpressed, thus leading to its progression and resistance to chemotherapy. Clausena excavata contains a coumarin called nordentatin, which has been shown to have anticancer properties. Particularly with regard to its function as a BCL-2 inhibitor, the underlying molecular mechanism is yet unknown. Objectives: The aim of this study was to determine the potential of nordentatin as a BCL-2 protein inhibitor through molecular docking and then validate it with molecular dynamics. Materials and Methods: Nordentatin's ADMET and bioactivity were estimated in silico. AutoDock Vina was used for molecular docking against BCL-2 using methotrexate as a comparison ligand and venetoclax as a reference ligand. PyMOL and Biovia Discovery Studio were then used for interaction analysis. Complex stability was assessed using a YASARA molecular dynamics simulation. Results: Nordentatin exhibits potential as an anti-inflammatory, anti-angiogenic, antioxidant, and anticancer drug based on bioactivity predictions. ADMET analysis showed that this compound is readily absorbed in the intestine, has moderate clearance, limited penetration into the central nervous system, and low toxicity, thus indicating a favorable pharmacokinetic and safety profile. Molecular docking results show that nordentatin has a fairly strong binding affinity for BCL-2 with a value of −7.4 kcal/mol, which is mainly influenced by hydrophobic and electrostatic interactions. Molecular dynamics simulations indicate that the BCL-2–nordentatin complex remains stable, with an RMSD value below ±2 Å, a compact Rg profile, and favorable RMSF fluctuations. Conclusion: The results indicate that nordentatin binds strongly and stably to BCL-2, thus offering potential for development as a BCL-2 inhibitor for oral cancer therapy.
Received date: 02-02-2026
Accepted date: 12-05-2026
Published date: 15-06-2026
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Warnakulasuriya S, Kerr AR. Oral Cancer Screening: Past, Present, and Future. J Dent Res. 2021;100(12):1313-1320. DOI: https://doi.org/10.1177/00220345211014795
Mitea G, Schröder V, Iancu IM, Mireșan H, Iancu V, Bucur LA, et al. Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma. Cancers (Basel). 2024;16(21):3612. DOI: https://doi.org/10.3390/cancers16213612
Siquara da Rocha LO, de Morais EF, de Oliveira LQR, Barbosa AV, Lambert DW, Gurgel Rocha CA, et al. Exploring beyond Common Cell Death Pathways in Oral Cancer: A Systematic Review. Biology (Basel). 2024;13(2):103. DOI: https://doi.org/10.3390/biology13020103
Sahin K, Orhan MD, Avsar T, Durdagi S. Hybrid In Silico and TR-FRET-Guided Discovery of Novel BCL-2 Inhibitors. ACS Pharmacol Transl Sci. 2021;4(3):1111-1123. DOI: https://doi.org/10.1021/acsptsci.0c00210
Tufail M, Hu JJ, Liang J, He CY, Wan WD, Huang YQ, et al. Hallmarks of cancer resistance. iScience. 2024;27(6):109979. DOI: https://doi.org/10.1016/j.isci.2024.109979
Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019;10(3):177. DOI: https://doi.org/10.1038/s41419-019-1407-6
Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023 Feb;28(1-2):20-38. DOI: https://doi.org/10.1007/s10495-022-01780-7
Arbab IA, Looi CY, Abdul AB, Cheah FK, Wong WF, Sukari MA, et al. Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition. Evid Based Complement Alternat Med. 2012; 2012:856029. DOI: https://doi.org/10.1155/2012/856029
Afriza D, Suriyah WH, Ichwan SJA, Knights J. Molecular Docking Analysis between Anti-apoptosis EGFR and Four Coumarins, and Four Carbazole Alkaloids. Padj J Dent. 2024; 36(1): 117-125. DOI: https://doi.org/10.24198/pjd.vol36no1.52467
Salem AH, Menon RM. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17(5): e13807. DOI: https://doi.org/10.1111/cts.13807
Pandya N, Jain N, Kumar A. Interaction analysis of anti-cancer drug Methotrexate with bcl-2 promoter stabilization and its transcription regulation. Gene Reports. 2021;23: 101155. DOI: https://doi.org/10.1016/j.genrep.2021.101155
Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chem Heterocycl Comp. 2014;50: 444–457. DOI: https://doi.org/10.1007/s10593-014-1496-1
Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015;58(9):4066-72. DOI: https://doi.org/10.1021/acs.jmedchem.5b00104
Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417-22. DOI: https://doi.org/10.1007/s10822-010-9352-6
Lim SV, Rahman MB, Tejo BA. Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus. BMC Bioinformatics. 2011;12 Suppl 13(Suppl 13):S24. DOI: https://doi.org/10.1186/1471-2105-12-S13-S24
Arcon JP, Turjanski AG, Martí MA, Forli S. Biased Docking for Protein-Ligand Pose Prediction. Methods Mol Biol. 2021;2266:39-72.. DOI: https://doi.org/10.1007/978-1-0716-1209-5_3
Alam M, Ali S, Mohammad T, Hasan GM, Yadav DK, Hassan MI. B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy. Int J Mol Sci. 2021;22(19):10442. DOI: https://doi.org/10.3390/ijms221910442
Qian C, Dai Y, Xu X, Jiang Y. HIF-1α Regulates Proliferation and Invasion of Oral Cancer Cells through Kv3.4 Channel. Ann Clin Lab Sci. 2019;49(4):457-467.
Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013;11: 118. DOI: https://doi.org/10.1186/1477-7819-11-118
Jamkhande P, Ghante M, Kshirsagar R. In Silico PASS Predictions and Exploration of Antioxidant and An-ti-inflammatory Activity of Citrus Karna Raf. Fruit. Medeni Med J. 2024;39(1):49-58. DOI: https://doi.org/10.4274/MMJ.galenos.2024.49775
Wang D, Jin J, Shi G, Bao J, Wang Z, Li S, et al. ADMET evaluation in drug discovery: 21. Ap-plication and industrial validation of machine learning algorithms for Caco-2 permeability prediction. J Cheminform. 2025;17(1):3. DOI: https://doi.org/10.1186/s13321-025-00947-z
Lee J, Beers JL, Geffert RM, Jackson KD. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment. Biomolecules. 2024;14(1):99. DOI: https://doi.org/10.3390/biom14010099
Xue Q, Liu X, Russell P, Li J, Pan W, Fu J, et al. Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock. Ecotoxicol Environ Saf. 2022 Mar 15;233:113323. DOI: https://doi.org/10.1016/j.ecoenv.2022.113323
Li J, Ma X, Guo S, Hou C, Shi L, Zhang H, et al. A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2. Glob Chall. 2020;4(12):2000067. DOI: https://doi.org/10.1002/gch2.202000067
Nyambo K, Tapfuma KI, Adu-Amankwaah F, Julius L, Baatjies L, Niang IS, et al. Molecular docking, molecular dynamics simulations and binding free en-ergy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria. Sci Rep. 2024;14(1):6794. DOI: https://doi.org/10.1038/s41598-024-57124-9
Gheidari D, Mehrdad M, Hoseini F. Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors. Front Pharmacol. 2024;15: 1360226. DOI: https://doi.org/10.3389/fphar.2024.1360226
Asfour HZ, Mohamed HM, Omar AM, Alhakamy NA, Mohamed GA, El-Agamy DS, et al. Molecular Docking and Dynamics Simulation Reveal Stable Binding of Tiliroside in the Colchicine Site of Tubulin. J Pharm Bioallied Sci. 2025;17(3):158-165. DOI: https://doi.org/10.4103/jpbs.jpbs_1414_25
Shimu MSS. Computational screening and molecular docking of compounds from Traditional Chinese Medicine (TCM) by targeting DNA topoisomerase I to design potential anticancer drugs. PLoS One. 2024;19(9): e0310364. DOI: https://doi.org/10.1371/journal.pone.0310364
Setyawati I, Setiawan AG, Nemchinova M, Vidilaseris K. The potential inhibitory mechanism of EGCG against the Chikungunya virus targeting non-structural protein 2 through molecular dynamics simulation. Sci Rep. 2024;14(1):29797. DOI: https://doi.org/10.1038/s41598-024-81287-0